Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)2042-2050
JournalDiabetes Care
Volume39
Issue number11
DOIs
Publication statusPublished - Nov 2016

Cite this